Epidermolysis Bullosa Market, by Product Type (Antibiotics, Analgesics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Epidermolysis bullosa is a genetic disorder characterized clinically by blister formation from mechanical trauma. There are four main types with additional sub-types identified. There is a spectrum of severity, and within each type, one may be either midely or severely affected. Epidermolysis bullosa range from being a minor inconvenience requiring modification of some activities, to being completely disabling and, in some cases, fatal.
Friction causes blister formation, blisters can form anywhere on the surface of the skin, within the oral cavity and in more severe forms many also involve the external surface of the eyes, as well as the respiratory, gastrointestinal and genitourinary tracts. In some form of the dieases,disfiguring scars and disabling musculoskeletal deformities occur.
Market Dynamics
The increasing prevalence of epidermolysis bullosa globally, rising research and development activities, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive the growth of the global epidermolysis bullosa market over the forecast period.
For instance, in March 2020, Abeona Therapeutics Inc., a gene and cell development company announced that the first patient treated in a pivotal phase III clinical trial evaluating EB - 101 gene therapy for recessive dystrophic epidermolysis bullosa.
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook